Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Genprex Inc (GNPX)

Genprex Inc (GNPX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 67,411
  • Shares Outstanding, K 47,809
  • Annual Sales, $ 0 K
  • Annual Income, $ -17,940 K
  • 60-Month Beta -0.54
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.53
Trade GNPX with:

Options Overview Details

View History
  • Implied Volatility 210.48%
  • Historical Volatility 90.33%
  • IV Percentile 99%
  • IV Rank 99.36%
  • IV High 211.42% on 11/26/21
  • IV Low 64.39% on 07/20/21
  • Put/Call Vol Ratio 21.97
  • Today's Volume 804
  • Volume Avg (30-Day) 238
  • Put/Call OI Ratio 0.59
  • Today's Open Interest 6,398
  • Open Int (30-Day) 4,691

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.20
  • Growth Rate Est. (year over year) +499,600.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3800 +2.17%
on 11/30/21
2.3900 -41.00%
on 11/04/21
-0.9300 (-39.74%)
since 11/01/21
3-Month
1.3800 +2.17%
on 11/30/21
3.3000 -57.27%
on 09/02/21
-1.7800 (-55.80%)
since 09/01/21
52-Week
1.3800 +2.17%
on 11/30/21
7.7200 -81.74%
on 02/08/21
-1.9600 (-58.16%)
since 12/01/20

Most Recent Stories

More News
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) CEO to Present in CEO Roadshow Webinar

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that the company’s president and chief...

GNPX : 1.4100 (-2.76%)
Genprex to Present in November CEO Roadshow Webinar

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced...

GNPX : 1.4100 (-2.76%)
Genprex Strengthens Management Team with Appointments of Industry Leaders Mark S. Berger, M.D. as Chief Medical Officer and Hemant Kumar, Ph.D. as Chief Manufacturing and Technology Officer

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced...

GNPX : 1.4100 (-2.76%)
Genprex to Participate in September Investor Conferences

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced...

GNPX : 1.4100 (-2.76%)
Genprex to Participate in a Monthly CEO Roadshow Webinar Series

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced...

GNPX : 1.4100 (-2.76%)
Proactive news headlines including Nextleaf Solutions, Genprex, Ready Set Gold, Sigma Lithium and Esports Entertainment

New York , June 23, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies:

VST.CN : 0.395 (-7.06%)
VSQTF : 0.3100 (-5.83%)
NBMFF : 0.2918 (+2.75%)
CNI.CN : 0.480 (-5.88%)
CLGUF : 0.3800 (-5.00%)
RDY.CN : 0.105 (-4.55%)
RDYFF : 0.0770 (+92.50%)
OILS.CN : 0.245 (unch)
OILFF : 0.1917 (unch)
GMBL : 4.65 (-8.10%)
BABY : 26.75 (-2.44%)
BABYF : 1.3200 (-5.71%)
Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced...

GNPX : 1.4100 (-2.76%)
Genprex Announces Participation in Noble Capital Markets’ Virtual Roadshow Series

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced...

GNPX : 1.4100 (-2.76%)
Genprex to Participate in Upcoming May Investor Conferences

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced...

GNPX : 1.4100 (-2.76%)
Proactive news headlines including Binovi Technologies, Genprex, Esports Entertainment Group and Golden Minerals Company

New York, May 06, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies:

IMTFF : 0.1216 (+13.64%)
BNVIF : 0.1200 (-21.82%)
VISN : 2.24 (-2.18%)
OILS.CN : 0.245 (unch)
OILFF : 0.1917 (unch)
BUZZ.CN : 0.060 (unch)
LMLLF : 0.0300 (-1.64%)
AUMN : 0.3850 (-6.10%)
GBR : 2.67 (-11.88%)
GTBAF : 15.3500 (-3.15%)
ABML : 1.1600 (-4.92%)
BHSC.CN : 0.340 (-2.86%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Genprex Inc. operates as a biotechnology company. It discovers and develops immunogene therapies for cancer treatment as well as clinical research, gene therapies, consulting and other related medical services. The company's initial product candidate is Oncoprex(TM) immunogene therapy which treats non-small...

See More

Key Turning Points

3rd Resistance Point 1.6400
2nd Resistance Point 1.5900
1st Resistance Point 1.5000
Last Price 1.4100
1st Support Level 1.3600
2nd Support Level 1.3100
3rd Support Level 1.2200

See More

52-Week High 7.7200
Fibonacci 61.8% 5.2981
Fibonacci 50% 4.5500
Fibonacci 38.2% 3.8019
Last Price 1.4100
52-Week Low 1.3800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar